Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
Cells|September 23, 2022
MARCKS as a Potential Therapeutic Target in Inflammatory Breast CancerMaroua Manai, Ines ELBini-Dhouib, Pascal Finetti, et al.Nature Communications|May 12, 2021
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomasZohreh Amoozgar, Jonas Kloepper, Jun Ren, et al.EMBO Reports|October 25, 2022
Loss of primary cilia promotes inflammation and carcinogenesisConception Paul, Ruizhi Tang, Ciro Longobardi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular CarcinomaLipika Goyal, Hui Zheng, Thomas A Abrams, et al.Blood|April 30, 2011
Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemiaMélanie Bonnet, Marie Loosveld, Bertrand Montpellier, et al.The Journal of Clinical Investigation|December 17, 2020
Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancerYuchen Guo, Monica Gabola, Rossano Lattanzio, et al.Cancers|October 13, 2021
CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAMGuillaume Belthier, Zeinab Homayed, Fanny Grillet, et al.Journal for Immunotherapy of Cancer|November 25, 2020
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinomaKohei Shigeta, Aya Matsui, Hiroto Kikuchi, et al.Blood|October 4, 2013
A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiencyBénédicte Neven, Emilie Mamessier, Julie Bruneau, et al.Nature Communications|January 24, 2015
Site- and allele-specific polycomb dysregulation in T-cell leukaemiaJean-Marc Navarro, Aurore Touzart, Lydie C Pradel, et al.Pageof 9